Development of a Shared UX Vision Based on UX Factors Ascertained Through Attribution

User experience (UX) is an important quality in differentiating products. For a product team, it is a challenge to develop a good positive user experience. A common UX vision for the product team supports the team in making goal-oriented decisions regarding the user experience. This paper presents an approach to developing a shared UX vision. This UX vision is developed by the product team while a collaborative session. To validate our approach, we conducted a first validation study. In this study, we conducted a collaborative session with two groups and a total of 37 participants. The group of participants comprised product managers, UX designers and comparable professional profiles. At the end of the collaborative session, participants had to fill out a questionnaire. Through questions and observations, we identified ten good practices and four bad practices in the application of our approach to developing a UX vision. The top 3 good practices mentioned by the participants include the definition of decision-making procedures (G1), determining the UX vision with the team (G2), and using general factors of the UX as a basis (G3). The top 3 bad practices are: providing too little time for the development of the UX vision (B1), not providing clear cluster designations (B2) and working without user data (B3). The results show that the present approach for developing a UX vision helps to promote a shared understanding of the intended UX in a quickly and simply way

Using Selective Electron Beam Melting to Enhance the High‐Temperature Strength and Creep Resistance of NiAl–28Cr–6Mo In Situ Composites

By increasing the density of interfaces in NiAl–CrMo in situ composites, the mechanical properties can be significantly improved compared to conventionally cast material. The refined microstructure is achieved by manufacturing through electron beam powder bed fusion (PBF‐EB). By varying the process parameters, an equiaxed or columnar cell morphology can be obtained, exhibiting a plate‐like or an interconnected network of the (Cr,Mo) reinforcement phase which is embedded in a NiAl matrix. The microstructure of the different cell morphologies is investigated in detail using scanning electron microscope, transmission electron microscopy, and atom probe tomography. For both morphologies, the mechanical properties at elevated temperatures are analyzed by compression and creep experiments parallel and perpendicular to the building direction. In comparison to cast NiAl and NiAl–(Cr, Mo), the yield strength of the PBF‐EB fabricated specimens is significantly improved at temperatures up to 1,027 °C. While the columnar morphology exhibits the best improved mechanical properties at high temperatures, the equiaxial morphology shows nearly ideal isotropic mechanical behavior, which is a substantial advantage over directionally solidified material.The additive manufacturing of NiAl–28Cr–6Mo in situ composites improves the mechanical properties significantly compared to conventionally cast material. By varying the process parameters, an equiaxed or columnar cell morphology can be obtained, exhibiting a plate‐like or an interconnected network of the (Cr,Mo) reinforcement phase. The yield strength of the PBF‐EB fabricated specimens is significantly improved at temperatures up to 1027 °C. image © 2023 WILEY‐VCH GmbH Deutsche Forschungsgemeinschaft http://dx.doi.org/10.13039/50110000165

Loss of serum and glucocorticoid-regulated kinase 3 (SGK3) does not affect proliferation and survival of multiple myeloma cell lines.

Multiple myeloma (MM) is a generally fatal plasma cell cancer that often shows activation of the phosphoinositide 3-kinase/Akt (PI3K/Akt) pathway. Targeted pharmacologic therapies, however, have not yet progressed beyond the clinical trial stage, and given the complexity of the PI3K/Akt signalling system (e.g. multiple protein isoforms, diverse feedback regulation mechanisms, strong variability between patients) it is mandatory to characterise its ramifications in order to better guide informed decisions about the best therapeutic approaches. Here we explore whether serum and glucocorticoid-regulated kinase 3 (SGK3), a potential downstream effector of PI3K, plays a role in oncogenic signalling in MM cells--either in concert with or independent of Akt. SGK3 was expressed in all MM cell lines and in all primary MM samples tested. Four MM cell lines representing a broad range of intrinsic Akt activation (very strong: MM.1s, moderate: L 363 and JJN-3, absent: AMO-1) were chosen to test the effects of transient SGK3 knockdown alone and in combination with pharmacological inhibition of Akt, PI3K-p110α, or in the context of serum starvation. Although the electroporation protocol led to strong SGK3 depletion for at least 5 days its absence had no substantial effect on the activation status of potential downstream substrates, or on the survival, viability or proliferation of MM cells in all experimental contexts tested. We conclude that it is unlikely that SGK3 plays a significant role for oncogenic signalling in multiple myeloma

Effects of a combination of plant bioactive lipid compounds and biotin compared with monensin on body condition, energy metabolism and milk performance in transition dairy cows

<div><p>The aim of this study was to test whether a combination of plant bioactive lipid compounds (also termed ‘essential oils’) and biotin (PBLC+B) could decrease the mobilization of body reserves and ketosis incidence in postpartum dairy cows. We compared non-supplemented control (CON) cows with cows receiving monensin (MON) as a controlled-release capsule at d -21, and with cows receiving PBLC+B from day (d) -21 before calving until calving (Phase 1) and further until d 37 after calving (Phase 2), followed by PBLC+B discontinuation from d 38 to d 58 (Phase 3). The PBLC+B cows had higher body weight and higher back fat thickness than CON cows and lesser body weight change than MON and CON cows in Phase 3. Body condition score was not different among groups. Milk protein concentration tended to be higher on the first herd test day in PBLC+B vs. CON cows. Milk fat concentration tended to be highest in PBLC+B cows throughout Phases 2 and 3, with significantly higher values in PBLC+B vs. MON cows on the second herd test day. Yields of energy-corrected milk were higher in PBLC+B vs. CON and MON cows in Phase 2 and higher in PBLC+B and MON cows vs. CON cows in Phase 3. The incidence of subclinical ketosis was 83%, 61% and 50% in CON, PBLC+B and MON cows, respectively, with lower mean β-hydroxybutyrate values in MON than in PBLC+B cows in Phase 1 prepartum. The serum triglyceride concentration was higher in PBLC+B vs. CON cows on d 37. No differences were observed in serum glucose, urea, non-esterified fatty acids, cholesterol and bilirubin concentrations. Aspartate transaminase and γ-glutamyltranspeptidase but not glutamate dehydrogenase activities tended to be highest in MON and lowest in PBLC+B in Phase 2. We conclude that PBLC+B prevent body weight loss after parturition and are associated with similar ketosis incidence and partly higher yields of energy-corrected milk compared to MON supplementation of dairy cows.</p></div

Milk performance on herd test days of cows receiving plant bioactive lipid compounds and biotin (PBLC+B) from d -21 to 37 relative to parturition, cows receiving a monensin bolus (MON) at d -21 or cows receiving no such supplements (CON).

<p>Milk performance on herd test days of cows receiving plant bioactive lipid compounds and biotin (PBLC+B) from d -21 to 37 relative to parturition, cows receiving a monensin bolus (MON) at d -21 or cows receiving no such supplements (CON).</p

Serum activities of enzymes in cows receiving plant bioactive lipid compounds and biotin (PBLC+B; n = 18) from d -21 to 37 relative to parturition, cows receiving a monensin bolus (MON; n = 18) at d -21 or cows receiving no such supplements (CON; n = 17).

<p>Serum activities of enzymes in cows receiving plant bioactive lipid compounds and biotin (PBLC+B; n = 18) from d -21 to 37 relative to parturition, cows receiving a monensin bolus (MON; n = 18) at d -21 or cows receiving no such supplements (CON; n = 17).</p

Milk robot visits, milk yield and milk composition of cows receiving plant bioactive lipid compounds and biotin (PBLC+B; n = 18) from d -21 to d 37 relative to parturition, cows receiving a monensin bolus (MON; n = 18) at d -21 or cows receiving no such supplements (CON; n = 17).

<p>Milk robot visits, milk yield and milk composition of cows receiving plant bioactive lipid compounds and biotin (PBLC+B; n = 18) from d -21 to d 37 relative to parturition, cows receiving a monensin bolus (MON; n = 18) at d -21 or cows receiving no such supplements (CON; n = 17).</p

Serum metabolite concentrations in cows receiving plant bioactive lipid compounds and biotin (PBLC+B; n = 18) from d -21 to 37 relative to parturition, cows receiving a monensin bolus (MON; n = 18) at d -21 or cows receiving no such supplements (CON; n = 17).

<p>Serum metabolite concentrations in cows receiving plant bioactive lipid compounds and biotin (PBLC+B; n = 18) from d -21 to 37 relative to parturition, cows receiving a monensin bolus (MON; n = 18) at d -21 or cows receiving no such supplements (CON; n = 17).</p

SGK3 expression in relation to (activated) signalling components of the PI3K/Akt system in MM cell lines.

<p>Shown are Western blots for PI3K pathway-associated signalling proteins or for their phosphorylated forms. Cells from the MM cell lines indicated were harvested from standard cell culture, the signals are thus representative of steady-state levels in culture. One cell lysate per line was used to load multiple gels. The representative β-actin control derives from the same blot on which SGK3 and P-FOXO1/3A were also stained. Note: the strong phospho-STAT3 signal in INA-6 cells results from permanent supplementation of the culture with recombinant human IL-6.</p